Cure8 research brief
The oral microbiome in children with Crohn's disease appears to reflect disease severity and changes with treatment, suggesting a potential noninvasive biomarker for monitoring response to nutritional therapies like CDED and EEN.
Pediatric Crohn's patients and caregivers; pediatric gastroenterologists and clinicians using nutritional therapy; microbiome and biomarker researchers.
This study randomized 54 pediatric participants to either the Crohn's Disease Exclusion Diet with partial enteral nutrition (CDED+PEN) or exclusive enteral nutrition (EEN) and collected oral swabs over 52 weeks for 16S rRNA sequencing. The oral microbiome differed by disease activity at baseline and tended to normalize as inflammation improved.
The MODI decreased with treatment and remission, with larger index changes reported in the CDED group between weeks 8–24. The authors note limited sampling at 24 weeks because of the COVID-19 pandemic and recommend further validation of the index in larger cohorts.
MODI is a proposed dysbiosis index derived from this study's data and validated against published datasets, but the authors call for further validation in larger, adequately powered studies. Sampling was limited at some timepoints due to COVID-19 disruptions.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
If sodium intake influences gut proteolytic activity, microbiota and inflammation, the findings could help tailor dietary guidance and personalized nutrition strategies for people with Crohn’s disease.
This story matters because it outlines a plausible way to extend the benefits of exclusive enteral nutrition (EEN) for Crohn's disease by using fecal microbiome transfer (FMT) to 'lock in' a healthier microbiome and...
Anti-drug antibodies can make anti-TNF biologics stop working for people with Crohn’s disease. This trial tests a simple, short antibiotic course given before starting anti-TNF therapy to see if it lowers antibody...
